A ten-year-old beagle with prostate cancer is helping researchers at TheUniversity of Queensland use nanomedicines to accurately diagnose and targetthe disease.

Hoover is the first patient in the world to receive the nanomedicine, whichthe research team hopes will help track and treat his cancer, and lead tobetter treatment for people with the same disease.

Nanomedicine is the science of developing tiny particles for applications inhealth – in this case therapeutics to specifically target a protein found inprostate cancer.

UQ Associate Professor Kris Thurecht said the new technology was important foradvancing cancer treatments.

“Chemotherapy is a common treatment for most cancers,” he said.

“Unfortunately, it can also cause serious side effects because it is notalways able to differentiate cancer cells from the healthy ones, sometimesdamaging healthy cells in the process.

“Nanomedicines with the ability to target specific areas can lead us to targetchemotherapy drugs to where they’re needed, and kill cancerous cells withminimal impact on healthy cells.

Dr Thurecht said pre-clinical studies had been successful in treating prostatecancer in the laboratory, leading to total remission in some cases.

“Validation of this science and technology in companion animals like Hoover isan exciting step forward in nanomedicine and towards human treatment,” hesaid.

Hoover was chosen for the trial because dogs – like humans – naturally developprostate cancer.

Dr Rod Straw, Veterinary Oncology Specialist and Director of BrisbaneVeterinary Specialist Centre and the Australian Animal Cancer Foundation, saidthe beagle could prove to be the vanguard for a revolution in health care.

“Cases like Hoover’s are very important to cancer research,” he said.

“We can learn to develop cancer treatments for not only pets but humans aswell.

“Our best friends may hold the key.”

Dr Kris Thurecht has an affiliation with UQ’s Centre for Advanced Imaging(CAI) and Australian Institute for Bioengineering and Nanotechnology (AIBN)..

Post navigation

Previous Pet Industry Reunion

Next Greencross considering sale of company

Leave a Reply

Your email address will not be published.